Amgen's most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $110.00 short put and a strike $100.00 long put offers a potential 11.86% return on risk over the next 37 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $110.00 by expiration. The full premium credit of $1.06 would be kept by the premium seller. The risk of $8.94 would be incurred if the stock dropped below the $100.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.
The RSI indicator is at 47.7 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2013
Thu, 14 Nov 2013 22:24:05 GMT
noodls – THOUSAND OAKS, Calif., Nov. 14, 2013 /PRNewswire/ — Amgen (NASDAQ:AMGN) will host a webcast investor meeting at the American Heart Association (AHA) Scientific Sessions 2013 on Tuesday, Nov. 19, at 7 …
Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2013
Thu, 14 Nov 2013 21:03:00 GMT
PR Newswire – THOUSAND OAKS, Calif., Nov. 14, 2013 /PRNewswire/ — Amgen (NASDAQ:AMGN) will host a webcast investor meeting at the American Heart Association (AHA) Scientific Sessions 2013 on Tuesday, Nov. 19, at 7 …
Amgen and Sanofi PCSK9 Drugs Can Reach U.S. Without Long Studies
Thu, 14 Nov 2013 20:42:06 GMT
Bloomberg – U.S. regulators won’t require Amgen Inc., Sanofi, Pfizer Inc. and other companies developing the next class of cardiovascular medicines to prove they prevent heart attacks and death before they’re approved….
Better Buy: Biogen or Amgen?
Thu, 14 Nov 2013 15:34:07 GMT
Motley Fool – Both Biogen and Amgen are fighting competition with new drugs with blockbuster potential, but is one a better buy than the other?
Watch The R&D Chiefs Of Pfizer, Merck, And Amgen Discuss The Drug Industry's Challenges
Thu, 14 Nov 2013 12:52:00 GMT
Forbes – Matthew Herper, Mikael Dolsten, Sean Harper & Roger Perlmutter A big moment at the Forbes Healthcare Summit last month: I was on stage with the R&D chief of three of the biggest drug companies on the planet. Roger Perlmutter, formerly of Amgen but now head of research at Merck, talked about […]
Related Posts
Also on Market Tamer…
Follow Us on Facebook